In Brief: Financial disclosure by clinical investigators
This article was originally published in The Tan Sheet
Executive Summary
Financial disclosure by clinical investigators: Public hearing on FDA's proposed regulation will be held on July 20 at the Wilson Auditorium on the NIH campus beginning at 9 a.m. The hearing will solicit comments on FDA's Sept. 24 proposed reg, which would require sponsors either to certify that investigators do not have financial arrangements that hinge on a study or to describe specific arrangements the company has taken to minimize investigator bias ("The Tan Sheet" Sept. 26, 1994, p. 14). The proposed reg would apply to investigators involved in OTC monograph studies...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning